CLNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Clene Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.29+0.19 (+6.13%)
Close on Oct 19, 2026
- Market cap
- $40.74M
- P/E (TTM)
- –
- Dividend yield
- –
Clene Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drugs Segment [Member] | – | – | – | – | – | – | – | – | – | – | – | $0 | – | – |
| Supplements Segment [Member] | – | – | – | – | – | – | – | – | – | – | – | $108.00K | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drugs Segment [Member] | – | – | – | – | – | – | – | – | – | – | – | -$9.62M | – |
| Supplements Segment [Member] | – | – | – | – | – | – | – | – | – | – | – | $80.00K | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $74.00K | $1.00K | $54.00K | $0 | $1.00K | $64.00K | $64.00K | $65.00K | $64.00K | $44.00K | $143.00K | $65.00K | 82.2% | +7300.0% |
| Royalty [Member] | $16.00K | $14.00K | $23.00K | $15.00K | $26.00K | $17.00K | $27.00K | $22.00K | $27.00K | $29.00K | $27.00K | $43.00K | 17.8% | -38.5% |
By region
From the segment and revenue-disaggregation notes of Clene's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.